Publication Date
7-1-2022
Journal
Journal of Food Allergy
DOI
10.2500/jfa.2022.4.220013
PMID
39021845
PMCID
PMC11250443
PubMedCentral® Posted Date
7-1-2022
PubMedCentral® Full Text Version
Post-print
Published Open-Access
yes
Keywords
egg allergy, oral immunotherapy, desensitization, children, shared decision-making
Abstract
Egg allergy usually develops in the first year of life, with an estimated prevalence of 2.6%-9%. Rates of resolution and timing vary, with approximately one-third of patients outgrowing their egg allergy by age 6 years. Persistent egg allergy has been associated with high egg white specific immunoglobulin E levels and sensitization to the egg allergen component Gal d 1, which is resistant to heat and digestion. These individuals seem to have a more severe and persistent phenotype of egg allergy. Recently, an active approach has emerged for patients with food allergy, including those with egg allergy, in the form of oral immunotherapy. Egg oral immunotherapy consists of the administration of gradually increasing doses of egg, with the aim to enable patients to consume small amounts of egg without having allergic reactions, which thus provides protection from accidental exposures to egg-containing foods. This article aims to discuss published evidence on egg oral immunotherapy, provide practical information on dosing protocols, and address special challenges associated with this intervention.
Included in
Allergy and Immunology Commons, Biological Phenomena, Cell Phenomena, and Immunity Commons, Medical Immunology Commons, Pediatrics Commons
